Equipment | March 28, 2024
Bionova Scientific’s process development capabilities are particularly highly regarded in the industry, and it has a rich track record regarding complex next-generation antibody drugs, which are typically challenging to manufacture
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)